Bendamustine's generic name is bendamustine hydrochloride [1].
When can generic bendamustine be available?
The patent expiry for bendamustine is a key factor in the availability of generic versions. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when market exclusivity ends and generic competition may emerge [2].
What are the brand names for bendamustine?
Bendamustine is marketed under brand names such as Treanda and Bendeka [3].
How is bendamustine used?
Bendamustine hydrochloride is a chemotherapy drug used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or after treatment with rituximab [3].
What are the potential side effects of bendamustine?
Patients receiving bendamustine may experience side effects such as low blood cell counts, nausea, vomiting, diarrhea, fever, fatigue, and hair loss [3].
How does bendamustine work?
Bendamustine is an alkylating agent. It works by damaging the DNA and RNA of cancer cells, which interferes with their growth and reproduction [3].
What is the cost of bendamustine?
The cost of bendamustine can vary significantly depending on the brand, dosage, and insurance coverage. Generic availability typically leads to lower prices [4].
What are the risks associated with bendamustine treatment?
In addition to common side effects, bendamustine treatment carries risks such as a potential for secondary cancers and severe skin reactions [3].
Who manufactures bendamustine?
Several pharmaceutical companies are involved in the manufacturing and marketing of bendamustine, including Teva Pharmaceuticals, which produces a generic version, and Acrotech Biopharma, which markets Bendeka [5][3].
What is the difference between Bendeka and Treanda?
Bendeka is a different formulation of bendamustine hydrochloride designed for shorter infusion times compared to Treanda [3].
What is the mechanism of action for bendamustine?
Bendamustine is classified as a nitrogen mustard. It functions as an alkylating agent by cross-linking DNA strands, which inhibits DNA synthesis and function, ultimately leading to cell death [3].
Where can I find more information about bendamustine patents?
Information regarding patents and exclusivity for bendamustine can be found on DrugPatentWatch.com [2].
What are the clinical trial results for bendamustine?
Clinical trials have demonstrated the efficacy of bendamustine in treating CLL and NHL. Studies have shown response rates and survival benefits in patients treated with bendamustine, often in combination with other therapies [3].
Are there alternative treatments for CLL and NHL?
Alternative treatments for CLL and NHL include other chemotherapy agents, targeted therapies, immunotherapy (such as rituximab), and stem cell transplantation, depending on the stage and specific characteristics of the disease [6].
What is the typical dosage and administration of bendamustine?
Dosage and administration of bendamustine depend on the type and stage of cancer being treated, as well as the patient's overall health. It is typically administered intravenously [3].
What regulatory approvals does bendamustine have?
Bendamustine has received approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) for the treatment of specific hematological malignancies [3].
What are patient concerns regarding bendamustine?
Patient concerns often revolve around managing side effects, understanding the treatment regimen, potential long-term risks, and the cost of treatment [3].
Sources:
[1] https://www.goodrx.com/bendamustine-hydrochloride
[2] https://drugpatentwatch.com/
[3] https://www.cancer.gov/drug-information/drug-bendamustine
[4] https://www.singlecare.com/prescription/bendamustine-hydrochloride
[5] https://www.drugs.com/history/treanda.html
[6] https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20351389